Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Chlorphenoxamine→

Chlorphenoxamine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
77-38-3
Molecular formula
C18H22ClNO
Molecular weight
303.8 g/mol
Drug class
First-generation antihistamine with antimuscarinic activityH1 receptor antagonist
Mechanism of action
Antagonises H1 histamine receptors and has anticholinergic effects, reducing itching and allergic symptoms. Some formulations have local antipruritic use.
Indications / reported uses
  • Symptomatic treatment of pruritus and selected allergic skin disorders with topical or systemic preparations in countries where chlorphenoxamine is authorised; current availability and indications are jurisdiction-specific

Sources: NLM MeSH — Chlorphenoxamine · PubMed — Chlorphenoxamine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Chlorphenoxamine Environmental Risk Assessment (ERA) (the Chlorphenoxamine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.